Fortress Biotech, Inc , a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products.
infoFortress Biotech is a micro cap stock with a total market cap of 57.03M.
infoThey trade on the NASDAQ and had their IPO 11 years and 9 months ago.
infoFortress Biotech currently employs 187 people.
infoAs of Wednesday, Aug 23 2023, Fortress Biotech’s share price is $0.4295.
News Relating to Fortress Biotech
GlobeNewsWire
Fortress Biotech to Present at the BTIG Virtual Biotechnology Conference 2023
Thursday Aug 03 2023 at 08:30
MIAMI, Aug. 03, 2023 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will present a corporate overview at the BTIG Virtual Biotechnology Conference on Tuesday, August 8, 2023 at 12:00 PM ET. The Company will also attend virtual one-on-one meetings during the conference.
GlobeNewsWire
Journey Medical Corporation to Announce Second Quarter 2023 Financial Results the Week of August 7, 2023
Wednesday Jul 19 2023 at 08:30
Company to host conference call to discuss financial results and provide a corporate update the week of August 7, 2023 Company to host conference call to discuss financial results and provide a corporate update the week of August 7, 2023
GlobeNewsWire
Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 22, 2023
Friday May 19 2023 at 16:01
Company to host conference call to discuss financial results and provide a corporate update on May 22, 2023 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a corporate update on May 22, 2023 at 4:30 p.m. ET
Zacks Investment Research
Fortress Biotech (FBIO) Reports Q1 Loss, Lags Revenue Estimates
Monday May 15 2023 at 18:59
Fortress Biotech (FBIO) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.18 per share a year ago.
GlobeNewsWire
Journey Medical Corporation to Announce Year End 2022 Financial Results on March 29, 2023
Wednesday Mar 22 2023 at 09:00
Company to host conference call to discuss financial results and provide a corporate update on March 29, 2023 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a corporate update on March 29, 2023 at 4:30 p.m. ET
GlobeNewsWire
Fortress Biotech to Participate in Two March 2023 Investor Conferences
Tuesday Mar 07 2023 at 08:00
MIAMI, March 07, 2023 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in two investor conferences in March 2023.
Zacks Investment Research
Fortress Biotech (FBIO) Reports Q3 Loss, Misses Revenue Estimates
Monday Nov 14 2022 at 18:48
Fortress Biotech (FBIO) delivered earnings and revenue surprises of 7.41% and 13.09%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Seeking Alpha
Fortress Biotech, Inc. (FBIO) Q3 2022 Earnings Call Transcript
Thursday Nov 10 2022 at 22:42
Fortress Biotech, Inc. (NASDAQ:FBIO ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Matt Blazei – CORE IR Claude Maraoui – Co-Founder President and Chief Executive Officer Ernie De Paolantonio – Chief Financial Officer Ramsey Alloush – General Counsel Srinivas Sidgiddi – Vice President of Clinical Development and Medical Affairs Conference Call Participants Scott Henry – ROTH Capital Partners Brandon Folkes – Cantor Fitzgerald Operator Ladies and gentlemen, thank you for standing by. Good afternoon and welcome to the Journey Medical’s Third Quarter 2022 Financial Results and Corporate Update Conference Call.
GlobeNewsWire
Journey Medical Corporation to Announce Third Quarter 2022 Financial Results on November 10, 2022
Thursday Nov 03 2022 at 08:52
Company to host conference call to discuss financial results and provide a corporate update on November 10, 2022 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a corporate update on November 10, 2022 at 4:30 p.m. ET
GlobeNewsWire
Fortress Biotech Announces Timing of Regular Monthly Dividend for October, November and December 2022 for its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock
Wednesday Oct 05 2022 at 08:30
MIAMI, Oct. 05, 2022 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (Common Stock: Nasdaq: FBIO) (Preferred Stock: Nasdaq: FBIOP) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced its board of directors has declared the regular monthly dividend of $0.1953125 per share of the Company’s 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (the “Series A Preferred Stock”) for the months of October, November and December 2022. The dividend will be payable on the last day of each month (October 31, November 30, and December 31) to holders of record as of the close of business on the fifteenth of that same month (October 15, November 15, December 15). Dividends will be paid in cash.
GlobeNewsWire
Journey Medical Corporation to Participate in Upcoming October 2022 Investor Conferences
Tuesday Oct 04 2022 at 08:30
SCOTTSDALE, Ariz., Oct. 04, 2022 (GLOBE NEWSWIRE) — Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, President and Chief Executive Officer, will participate in two upcoming investor conferences.
GlobeNewsWire
Fortress Biotech to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Thursday Sep 08 2022 at 08:30
MIAMI, Sept. 08, 2022 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress” or “the Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced that Lindsay A. Rosenwald, M.D., Chairman and Chief Executive Officer, will present a corporate update virtually at the H.C. Wainwright 24th Annual Global Investment Conference and the Company will participate in one-on-one meetings on Tuesday, September 13, 2022.
Zacks Investment Research
Fortress Biotech (FBIO) Reports Q2 Loss, Misses Revenue Estimates
Thursday Aug 11 2022 at 18:49
Fortress Biotech (FBIO) delivered earnings and revenue surprises of -20% and 17.35%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Seeking Alpha
Journey Medical Corporation (FBIO) CEO Claude Maraoui on Q2 2022 Results – Earnings Call Transcript
Tuesday Aug 09 2022 at 21:05
Journey Medical Corporation (NASDAQ:FBIO ) Q2 2022 Results Conference Call August 9, 2022 4:30 PM ET Company Participants Claude Maraoui – Co-Founder President and Chief Executive Officer Ernest De Paolantonio – Chief Financial Officer Ramsey Alloush – General Counsel Dr. Srinivas Sidgiddi – Vice President of Clinical Development and Medical Affairs Conference Call Participants Brandon Folkes – Cantor Fitzgerald Mayank Mamtani – B. Riley FBR Operator Ladies and gentlemen, thank you for standing by.
GlobeNewsWire
Fortress Biotech to Participate in Two Upcoming May 2022 Investor Conferences
Wednesday May 18 2022 at 08:30
MIAMI, May 18, 2022 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in two investor conferences in May 2022.
Zacks Investment Research
Fortress Biotech (FBIO) Reports Q1 Loss, Tops Revenue Estimates
Thursday May 12 2022 at 18:48
Fortress Biotech (FBIO) delivered earnings and revenue surprises of 35.71% and 19.27%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewsWire
Fortress Biotech to Present at the 21st Annual Needham Virtual Healthcare Conference
Thursday Apr 07 2022 at 08:30
MIAMI, April 07, 2022 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will present a corporate update at the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022, at 1:30 p.m. ET and will participate in one-on-one meetings during the conference.
GlobeNewsWire
Fortress Biotech Announces Virtual Two-Day R&D Summit Hosted by B. Riley Securities on Tuesday, April 5 and Wednesday, April 6, 2022
Friday Apr 01 2022 at 08:30
MIAMI, April 01, 2022 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced a two-day summit hosted by the B. Riley Securities’ Healthcare Equity Research team, that will feature multiple programs from Fortress’ diversified pipeline. The events will be held virtually on Tuesday, April 5, and Wednesday, April 6, 2022, beginning at 1:00 p.m. ET each day.
GlobeNewsWire
Fortress Biotech to Participate in Three March 2022 Investor Conferences
Wednesday Mar 09 2022 at 09:00
MIAMI, March 09, 2022 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in three investor conferences in March 2022.
GlobeNewsWire
Fortress Biotech Announces Virtual Two-Day Corporate Access Summit Hosted by B. Riley Securities on Tuesday, April 5 and Wednesday, April 6, 2022
Thursday Mar 03 2022 at 08:00
MIAMI, March 03, 2022 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced a two-day summit hosted by the B. Riley Securities’ Healthcare Equity Research team, that will feature multiple programs from Fortress’ diversified pipeline. The events will be held virtually on Tuesday, April 5, and Wednesday, April 6, 2022, beginning at 1:00 p.m. ET each day.
GlobeNewsWire
Fortress Biotech to Participate in the 2nd Annual Winter Wonderland Best Ideas Virtual Investor Conference
Monday Feb 07 2022 at 08:30
MIAMI, Feb. 07, 2022 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will present a corporate update at the 2nd Annual Winter Wonderland Best Ideas Virtual Investor Conference on Wednesday, February 9, 2022, at 9:30 a.m. ET and will participate in one-on-one meetings during the conference.
GlobeNewsWire
Fortress Biotech to Participate in the H.C. Wainwright BioConnect Virtual Conference
Thursday Jan 06 2022 at 08:30
MIAMI, Jan. 06, 2022 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in the H.C. Wainwright BioConnect Virtual Conference scheduled to take place from Monday, January 10 through Thursday, January 13, 2022. The company’s presentation will be available for on-demand viewing on Fortress’ website beginning Monday, January 10, 2022, at 7:00 a.m. EST and will remain available on the Events page under the News & Media section of Fortress’ website: http://www.fortressbiotech.com for approximately 30 days following the presentation.
Zacks Investment Research
Fortress Biotech (FBIO) Reports Q3 Loss, Tops Revenue Estimates
Monday Nov 15 2021 at 18:29
Fortress Biotech (FBIO) delivered earnings and revenue surprises of -225.00% and 14.52%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Seeking Alpha
Journey Medical Corporation: Fortress Biotech Subsidiary Files For IPO
Friday Oct 29 2021 at 07:31
Journey Medical Corporation: Fortress Biotech Subsidiary Files For IPO
GlobeNewsWire
Fortress Biotech to Participate in Dawson James Securities’ 6th Annual Small Cap Growth Conference
Monday Oct 18 2021 at 08:30
NEW YORK, Oct. 18, 2021 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will present a corporate update at Dawson James Securities’ 6th Annual Small Cap Growth Conference on Thursday, October 21, 2021, at 1:10 p.m. ET and will participate in one-on-one meetings during the conference.
Pulse2
FBIO Stock: Why It Increased This Week
Thursday Oct 14 2021 at 11:33
The stock price of Fortress Biotech (NASDAQ: FBIO) increased by over 6% this past week. This is why it happened.
PRNewsWire
Fortress Biotech and Cyprium Therapeutics Announce Positive Clinical Data for CUTX-101, Copper Histidinate, Presented at 2021 American Academy of Pediatrics National Conference & Exhibition
Wednesday Oct 13 2021 at 19:29
NEW YORK and SOLANA BEACH, Calif., Oct. 13, 2021 /PRNewswire/ — Cyprium Therapeutics, Inc. (“Cyprium”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) partner company, with support from its licensing partner Sentynl Therapeutics, Inc. (“Sentynl”), a wholly owned subsidiary of Cadila Healthcare Limited (“Zydus”), today announced positive results from an efficacy and safety analysis of data integrated from two completed pivotal studies in patients with Menkes disease treated with CUTX-101, copper histidinate (CuHis).
Zacks Investment Research
Fortress’ (FBIO) Partner Meets Study Goal for Menkes Disease
Monday Oct 11 2021 at 12:17
Cyprium Therapeutics, a partner company of Fortress Biotech (FBIO), reports positive data from two pivotal studies evaluating CUTX-101 in patients with Menkes disease.
GlobeNewsWire
Fortress Biotech and Cyprium Therapeutics Announce Positive Clinical Data for CUTX-101, Copper Histidinate, Presented at 2021 American Academy of Pediatrics National Conference & Exhibition
Friday Oct 08 2021 at 08:00
Cyprium Therapeutics, a partner company of Fortress Biotech, is developing CUTX-101 for the treatment of Menkes disease
GlobeNewsWire
Fortress Biotech Announces Closing of Acquisition of Caelum Biosciences by AstraZeneca
Wednesday Oct 06 2021 at 08:00
Triggers upfront payment of approximately $150 million to Caelum shareholders, of which approximately $64 million is payable to Fortress Biotech 1
Fortress Biotech Bankruptcy Risk
The Altman Z-score is a formula that measures a company’s financial health and bankruptcy risk. It assigns a numerical score based on various financial ratios. The Z-score is divided into different zones. If the Z-score is above 2.99, it indicates a lower bankruptcy risk, classifying the company as ‘safe’ or ‘non-distressed’. If the score falls below 1.81, it suggests a higher risk, indicating potential financial distress or bankruptcy. The range between 1.81 and 2.99 is called the ‘gray zone’ or zone of ambiguity.
Learn more at Investopediaopen_in_new
Fortress Biotech’s Altman Z-score is -8.65 which is in the distress zone. This indicates a higher risk of financial distress and potential bankruptcy for the company. It can serve as a warning sign of significant financial challenges, requiring careful consideration by potential investors.
Derived from SEC.GOV filing dataopen_in_new
Fortress Biotech Insider Trading
Insider trading is when individuals employed by a company buy or sell its securities following legal procedures and regulations. Company executives, directors, and employees may be permitted to buy or sell shares if they follow specific rules, such as filing a Form 4 with the SEC within two business days.
Learn more at Investopediaopen_in_new
Over the last 3 months, there has been no insider trading in Fortress Biotech.
Derived from SEC.GOV filing dataopen_in_new
Debt & Income Analysis
Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.
Learn more at WallStreetPrepopen_in_new
Fortress Biotech’s Income Quality of 1.35 is greater than its Industry Group of 0.69 (95.7% greater)
Fortress Biotech’s Income Quality of 1.35 is greater than its Major Industry Group of 0.71 (90.1% greater)
Fortress Biotech’s Income Quality of 1.35 is greater than its Sector of 0.75 (80.0% greater)
Derived from SEC.GOV filing dataopen_in_new
Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.
Learn more at Investopediaopen_in_new
Fortress Biotech’s Current Ratio of 0.99 is lower than its Industry Group of 4.76 (-79.2% lower)
Fortress Biotech’s Current Ratio of 0.99 is lower than its Major Industry Group of 4.32 (-77.1% lower)
Fortress Biotech’s Current Ratio of 0.99 is lower than its Sector of 2.6 (-61.9% lower)
Derived from SEC.GOV filing dataopen_in_new
Value Analysis
PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.
Learn more at Investopediaopen_in_new
Cannot compare a negative PE Ratio (-0.46 & -1.27)
Cannot compare a negative PE Ratio (-0.46 & -1.1)
Cannot compare a negative PE Ratio (-0.46 & -0.4)
Derived from SEC.GOV filing dataopen_in_new
The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.
Learn more at Investopediaopen_in_new
Cannot compare a negative PB Ratio (-3.58 & 1.34)
Cannot compare a negative PB Ratio (-3.58 & 1.4)
Cannot compare a negative PB Ratio (-3.58 & 1.62)
Derived from SEC.GOV filing dataopen_in_new
Efficiency Analysis
ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.
Learn more at Investopediaopen_in_new
Fortress Biotech’s ROE of 7.77 is greater than its Industry Group of -0.44 (1865.9% greater)
Fortress Biotech’s ROE of 7.77 is greater than its Major Industry Group of -0.38 (2144.7% greater)
Fortress Biotech’s ROE of 7.77 is greater than its Sector of -0.03 (26000.0% greater)
Derived from SEC.GOV filing dataopen_in_new
ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.
Learn more at Investopediaopen_in_new
Fortress Biotech’s ROCE of -4.08 is lower than its Industry Group of -0.42 (-871.4% lower)
Fortress Biotech’s ROCE of -4.08 is lower than its Major Industry Group of -0.37 (-1002.7% lower)
Fortress Biotech’s ROCE of -4.08 is lower than its Sector of -0.04 (-10100.0% lower)
Derived from SEC.GOV filing dataopen_in_new